Forensische Psychophysiologie

Dieses Experiment untersuchte die Effekte der unterschiedlichen Fragen- bzw. Itemtypen (Stimuli), des Wahrheitsgehalts der Antworten und der elektrodermalen Labilität auf die Hautleitfähigkeitsreaktionen (SCR) und die phasische Herzschlagfrequenz (HR) für zwei relativ neue Befragungstechniken der forensischen Psychophysiologie ('Lügendetektion'): Directed Lie Test (DLT) und Guilty Actions Test (GAT).Achtzig Männer begingen einen simulierten Schmuckdiebstahl. Jeweils die Hälfte entwendete entweder einen Ring oder eine Kette. Während dieser Tat wurden jedoch alle Probanden mit den kritischen Details beider Scheinverbrechen konfrontiert. Anschließend absolvierten sie entweder einen DLT oder einen GAT. Die relevanten Stimuli der Tests bezogen sich auf beide Scheinverbrechen und wurden - intraindividuell variiert - wahrheitswidrig und wahrheitsgemäß verneint. Darüber hinaus umfaßte der DLT inhaltlich parallelisierte Paare von Kontrollfragen. Die Probanden wurden instruiert, die jeweiligen Kontrollfragen eines Paars wahrheitswidrig versus wahrheitsgemäß zu verneinen. Die Testverfahren beinhalteten außerdem nicht tatbezogene, irrelevante Stimuli, die wahrheitsgemäß beantwortet wurden. Für beide Befragungstechniken fand man Reaktionsunterschiede zwischen den Stimulustypen, insbesondere stärkere SCR-Magnituden und eine niedrigere HR auf die wahrheitswidrig verneinten relevanten Stimuli. Bei den Kontrollfragen des DLT zeigten sich jedoch keine signifikanten Effekte des Wahrheitsgehalts. Die elektrodermale Labilität hatte keinen bedeutsamen Einfluß auf die Reaktionsunterschiede. Die Ergebnisse wurden vor allem anhand psychophysiologischer Theorien der Aufmerksamkeit, Konflikte und Informationsverarbeitung interpretiert.

In vitro generation and characterization of acute myeloid leukemia-reactive CD8 + cytotoxic T-lymphocyte clones from healthy donors

Donor-derived CD8+ cytotoxic T lymphocytes (CTLs) eliminating host leukemic cells mediate curative graft-versus-leukemia (GVL) reactions after allogeneic hematopoietic stem cell transplantation (HSCT). The leukemia-reactive CTLs recognize hematopoiesis-restricted or broadly expressed minor histocompatibility and leukemia-associated peptide antigens that are presented by human leukocyte antigen (HLA) class I molecules on recipient cells. The development of allogeneic CTL therapy in acute myeloid leukemia (AML) is hampered by the poor efficiency of current techniques for generating leukemia-reactive CTLs from unprimed healthy donors in vitro. In this work, a novel allogeneic mini-mixed lymphocyte/leukemia culture (mini-MLLC) approach was established by stimulating CD8+ T cells isolated from peripheral blood of healthy donors at comparably low numbers (i.e. 10e4/well) with HLA class I-matched primary AML blasts in 96-well microtiter plates. Before culture, CD8+ T cells were immunomagnetically separated into CD62L(high)+ and CD62L(low)+/neg subsets enriched for naive/central memory and effector memory cells, respectively. The application of 96-well microtiter plates aimed at creating multiple different responder-stimulator cell compositions in order to provide for the growth of leukemia-reactive CTLs optimized culture conditions by chance. The culture medium was supplemented with interleukin (IL)-7, IL-12, and IL-15. On day 14, IL-12 was replaced by IL-2. In eight different related and unrelated donor/AML pairs with complete HLA class I match, numerous CTL populations were isolated that specifically lysed myeloid leukemias in association with various HLA-A, -B, or -C alleles. These CTLs recognized neither lymphoblastoid B cell lines of donor and patient origin nor primary B cell leukemias expressing the corresponding HLA restriction element. CTLs expressed T cell receptors of single V-beta chain families, indicating their clonality. The vast majority of CTL clones were obtained from mini-MLLCs initiated with CD8+ CD62L(high)+ cells. Using antigen-specific stimulation, multiple CTL populations were amplified to 10e8-10e10 cells within six to eight weeks. The capability of mini-MLLC derived AML-reactive CTL clones to inhibit the engraftment of human primary AML blasts was investigated in the immunodeficient nonobese diabetic/severe combined immune deficient IL-2 receptor common γ-chain deficient (NOD/SCID IL2Rγnull) mouse model. The leukemic engraftment in NOD/SCID IL2Rγnull was specifically prevented if inoculated AML blasts had been pre-incubated in vitro with AML-reactive CTLs, but not with anti-melanoma control CTLs. These results demonstrate that myeloid leukemia-specific CTL clones capable of preventing AML engraftment in mice can be rapidly isolated from CD8+ CD62L(high)+ T cells of healthy donors in vitro. The efficient generation and expansion of these CTLs by the newly established mini-MLLC approach opens the door for several potential applications. First, CTLs can be used within T cell-driven antigen identification strategies to extend the panel of molecularly defined AML antigens that are recognizable by T cells of healthy donors. Second, because these CTLs can be isolated from the stem cell donor by mini-MLLC prior to transplantation, they could be infused into AML patients as a part of the stem cell allograft, or early after transplantation when the leukemia burden is low. The capability of these T cells to expand and function in vivo might require the simultaneous administration of AML-reactive CD4+ T cells generated by a similar in vitro strategy or, less complex, the co-transfer of CD8-depleted donor lymphocytes. To prepare clinical testing, the mini-MLLC approach should now be translated into a protocol that is compatible with good manufacturing practice guidelines.